Annals of Hepatology

Article	Citations
IGF-1 alleviates CCL4-induced hepatic cirrhosis and dysfunction of intestinal barrier through inhibition TLR4/NF-κB signaling mediated by down-regulation HMGB1	219
Prevalence of non alcoholic fatty liver disease and associated factors?	100
Reply to: “correspondence about “Efficacy and safety of basiliximab”	75
Targeting cellular senescence as a therapeutic approach in non-alcoholic steatohepatitis	73
The rationale for the aggressive progression of MASLD in patients with type 2 diabetes	69
FLI and FIB-4 in diagnosing metabolic dysfunction-associated steatotic liver disease in primary care: High prevalence and risk of significant disease	42
Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19)	39
Renal and brain failure predict mortality of patients with acute-on-chronic liver failure admitted to the intensive care unit	38
Unexpected findings of hepatitis B and delta infection in northeastern Brazil: A public health alert	36
P-27 ALTERATION IN LIVER FUNCTION TESTS AMONG PATIENTS HOSPITALIZED FOR COVID-19: A MULTICENTRIC STUDY IN PERU	36
Correspondence on “prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection”	30
P-8 PRESERVATION OF THROMBIN GENERATION IN CIRRHOSIS DESPITE ABNORMAL RESULTS OF INTERNATIONAL NORMALIZED RATIO: IMPLICATIONS FOR INVASIVE PROCEDURES	29
O-18 IMPAIRED ANTI-HBV VACCINE RESPONSE IN NON-CIRRHOTIC CHRONIC HCV PATIENTS IS NOT OVERCOME BY DOUBLE DOSE REGIMEN. FOURTH DOSE MAYBE THE ANSWER!	28
P-58 CONCORDANCE BETWEEN ECOGRAPHY AND THE CONTINUOUS ATTENUATION PARAMETER (CAP) BY TRANSIENT ELASTOGRAPHY FOR THE DIAGNOSIS OF LIVER STEATOSIS	28
O-7 PREVALENCE, CHARACTERIZATION AND SURVIVAL OF ACUTE-ON-CHRONIC LIVER FAILURE IN A CHILEAN UNIVERSITY HOSPITAL	28
COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern on cases with underlying liver problem	26
P-89 ASSESSMENT OF HEPATIC FIBROSIS IN TYPE 2 DIABETIC PATIENTS: A CROSS SECTIONAL ANALYSIS	25
P-118 NONINVASIVE PARAMETERS OF PREDICTORS OF ESOPHAGEAL VARICES (EV) IN CHILDREN WITH INTRAHEPATIC PORTAL HYPERTENSION	24
P-112 ALPHA-FETOPROTEIN AS A PROGNOSTIC FACTOR IN PATIENTS WITH HEPATOCELLULAR CARCINOMA SUBMITTED TO LIVER TRANSPLANTATION – BRAZILIAN MULTICENTER STUDY	22
P-98 BIOCHEMICAL MAKERS AMONG CHRONIC LIVER DISEASE PATIENTS ACCORDING COVID-19 INFECTION: A FOLLOW-UP STUDY	22
Knockdown of long non-coding RNA LINC01006 represses the development of hepatocellular carcinoma by modulating the miR-194-5p/CADM1 axis	21
A MULTICENTER REAL-WORLD COHORT TO VALIDATE THE EFFICACY AND SAFETY OF DIRECT ANTIVIRAL AGENTS FOR HEPATITIS C, AND RELATED RISK FACTORS FOR NON-SVR IN DECOMPENSATED CIRRHOSIS	21
Andrew K. Burroughs: a research hepatologist extraordinaire	20
Progression of intraductal papillary neoplasm of the bile duct (IPNB): A proposed model through the observation of patients with non-resected tumors	20
Prevalence of hepatitis B and C viral infections in hospitalized patients with increased liver enzyme levels and with no known history of hepatic disease	20

P-85 USE OF LOW DOSES OF GENERIC TACROLIMUS AND THERAPEUTIC LEVELS IN LIVER TRANSPLANT PATIENTS: RESULTS FROM A SINGLE CENTER IN PERU	19
P-55 QUALITY OF LIFE IMPROVES IN PATIENTS WITH OR WITHOUT CIRRHOSIS AFTER HEPATITIS C CURE WITH DIRECT-ACTING ANTIVIRAL AGENTS	19
P-108 CORONAVIRUS DISEASE (COVID-19) IN LIVER TRANSPLANT PATIENTS: A SINGLE CENTER EXPERIENCE IN BOGOTÁ COLOMBIA	19
PREVALENCE OF COMBINED LIVER DAMAGE IN MEXICAN POPULATION	18
Differences in mortality and prognostic scales according to ACLF grade	18
FREQUENCY OF HEPATIC FUNCTION ALTERATION IN MEXICAN PATIENTS WITH COVID-19 AND ITS ASSOCIATION WITH THE SEVERITY OF ACUTE RESPIRATORY DISTRESS SYNDROME: PRELIMINARY RESULTS	18
Analysis of the complete genome of HBV genotypes F and H found in Brazil and Mexico using the next generation sequencing method	18
An unusual complication after variceal band ligation: complete esophageal obstruction, a case report and review of the literature	17
Characteristics of patients with acute over chronic liver failure (ACLF) and risk of mortality due to amount of alcohol, MELD and MELD NA	17
Precipitating factors of kidney injury in patients with liver cirrhosis	17
EFFICACY AND SAFETY OF TERLIPRESSIN INFUSION VS BOLUS TREATMENT IN DIGESTIVE BLEEDING OF VARICEAL ORIGIN AT THE PUEBLA SPECIALTY HOSPITAL, PRELIMINARY RESULTS	17
Prevalence of hepatobiliary manifestations and its relationship with the time of evolution of inflammatory bowel disease in patients attended at Centro Médico Nacional 20 de noviembre	17
Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease	16
Editorial Board	16
MELD Na and MELD 3.0 have the best performance in predicting the risk of death at 28 days in patients with severe alcoholic hepatitis in the Mexican population	14
P-21 BONE MASS, VITAMIN D LEVELS AND NONALCOHOLIC FATTY FIVER DISEASE	14
P-18 PREVALENCE AND EPIDEMIOLOGICAL CHARACTERISTICS OF INFECTIONS IN PATIENTS WITH CHRONIC LIVER DISEASE: RETROSPECTIVE ANALYSIS FROM A GENERAL HOSPITAL IN MONTERREY, NUEVO LEON, MEXICO	14
Short-term efficacy and safety of l-ornithine l-aspartate therapy in patients with cirrhosis and minimal hepatic encephalopathy: a real-life cohort study	14
P-59 LIVER TRANSPLANTATION: SIX YEARS EXPERIENCE IN A UNIVERSITY HOSPITAL OF CHILE	14
P-91 PREVALENCE OF HEPATITIS C VIRUS INFECTION DETECTED BY RAPID TEST IN A HIGH-RISK POPULATION	14
Reply to: Lactate-dehydrogenase associated with mortality in hospitalized patients with COVID-19 in Mexico	14
Milestones in Hepatology	14
P-26 PORTAL VENOUS THROMBOSIS IN TRANSPLANTED CIRRHOTIC PATIENTS AT THE “HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE”	14
P-64 THE ALCOHOL-ASSOCIATED LIVER DISEASE PARADOX IN CHILE: AN ASSESSMENT WITH DATA FROM THE NATIONAL HEALTH SURVEY (ENS 2016-2017)	13
O-12 MIR-181A AS A BIOMARKER OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE	13
O-11 REMODELING OF IMMUNOLOGICAL BIOMARKERS IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH DIRECTACTING ANTIVIRAL THERAPY	13
P-123 PROFILE OF NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) X TREATMENT: A NUTROLOGY'S VIEW	13
P-43 INDICATORS OF RESPONSE TO FIRST TRANSARTERIAL CHEMOEMBOLIZATION (TACE) IN HEPATOCELULLAR CARCINOMA	13
FREQUENCY OF RISK FACTORS FOR DEVELOPMENT OF METABOLIC FATTY LIVER DISEASE (MAFLD) IN A CENTER OF CONCENTRATION OF LIVER DISEASES	12
P-71 EVALUATION OF ANXIETY AND DEPRESSION IN PATIENTS WITH CIRRHOSIS AND THE IMPACT ON THE QUALITY OF LIFE	12
CONNECTIVE TISSUE GROWTH FACTOR (CTGF) AS A PROMOTER IN THE DEVELOPMENT OF FIBROSIS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS	12
O-21 SOLUBLE CD163 PERFORMANCE AS A NON-INVASIVE BIOMARKER OF DIFFERENT LIVER CONDITIONS	12
P-107 EPIDEMIOLOGICAL AND CLINICAL PROFILE OF AUTOIMMUNE HEPATITIS IN A BRAZILIAN TERTIARY HOSPITAL	12
Etiology and find in portal vein thrombosis at the Hospital de Especialidades del Centro Médico Nacional La Raza	12
NEOBUXBAMIA TETETZO AS A CAUSE OF DRUG-INDUCED LIVER INJURY	12
Efficacy and safety of treatment with terlipressin infusion vs. bolus in gastrointestinal bleeding of variceal origin in a third-level hospital	12
P-78 USE OF ARTERIAL CONDUITS IN LIVER TRANSPLANTATION: OUTCOMES IN A SINGLE CENTRE IN PERU	12
Susceptibility to liver damage in women due to risky alcohol consumption	11
A novel nomogram for predicting HBeAg seroclearance in HBeAg-positive chronic hepatitis B patients treated with nucleos(t)ide analogues	11
A thorny matter: Spur cell anemia	11
Systematic review and meta-analysis: Transient elastography compared to liver biopsy for staging of liver fibrosis in primary biliary cholangitis	11
Genome-wide DNA methylation and transcriptomic analysis of liver tissues subjected to early ischemia/reperfusion injury upon human liver transplantation	11
Gut dysbiosis in alcoholic liver disease: Wonderful dilemma?	11
High prevalence of periodontal disease in patients with NASH- possible association of poor dental health with NASH severity	11
Laparoscopic repair of transected right hepatic artery during cholecystectomy: A report of two cases	11
Activation of the NLRP3 inflammasome by CCl4 exacerbates hepatopathogenic diet-induced experimental NASH	11
Liver fibrosis: More than meets the eye	11
O-17 NUTRICIONAL AND PHYSICAL THERAPHY IMPROVES LIVER FRAILTY INDEX IN LISTED PATIENTS WITH CIRRHOSIS: RANDOMIZED CONTROLLED TRIAL. INTERIM ANALYSIS	10
P-129 LIVER TRANSPLANTATION IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA. EXPERIENCE OF TWO CASES AT AN ARGENTINE HHT REFERRAL CENTER	10
O-1 ECONOMIC IMPACT OF LONG-TERM ALBUMIN INFUSIONS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS AND UNCOMPLICATED ASCITES FROM THE BRAZILIAN PUBLIC AND PRIVATE HEALTHCARE SYSTEMS PERSPECTIVES	10

CSNK2A2 promotes hepatocellular carcinoma progression through activation of NF-κB pathway	10
O-30 ALCOHOL-HARM PARADOX IN LATIN AMERICA: HOW TO STUDY IT DESPITE DATA LIMITATIONS? THE CHILEAN EXPERIENCE	10
P-118 HEPATOCELLULAR CARCINOMA. AN EXPERIENCE IN A TRANSPLANT CENTER IN COLOMBIA	10
Utility of the MELD and MELD-Lactate scale in patients with severe Alcoholic Hepatitis as a predictor of severity and early mortality.	10
O-12 CHARACTERIZATION AND UTILIZATION OF HCV-POSITIVE DONORS IN ARGENTINA	10
O-22 DIFFERENTIAL MUTATION PATTERN ASSOCIATED WITH HEPATITIS B E ANTIGEN SEROCONVERSION BETWEEN SUBGENOTYPE F1b CLUSTERS: POTENTIAL ROLE IN PATHOGENESIS	10
cccDNA epigenetic regulator as target for therapeutical vaccine development against hepatitis B	10
O-20 EFFECTS OF ISOCALORIC AND NEGATIVE CALORIE BALANCE EXERCISE ON SERUM LEVELS OF INSULIN-LIKE GROWTH FACTOR TYPE 1 IN SUBJECTS WITH INITIAL AND ADVANCED FATTY LIVER	9
Pirfenidone induces translocation of sirt1 to nucleus and deacetylation of histone 3 slows down the development of fibrosis and tumorigenicity in a experimental model of hepatocarcinoma.	9
Bouveret syndrome, a rare clinical presentation of abdominal pain in a patient with diabetic ketoacidosis: A case report.	9
Levels of IGFBP-1, 3 and 7 in human serum induced by alcohol consumption, NAFLD and dual insult	9
Intrahepatic Cholestasis Induced by Leflunomide: An Unusual Presentation of DILI	9
Association of IFNL3 gene rs4803217 with spontaneous clearance of Hepatitis C virus in patients from West Mexico	9
Epidemiology and demographic aspects in patients with acute on chronic liver failure in a third-level care hospital in Mexico.	9
Segmental portal hypertension secondary to chronic pancreatitis	9
O-3 DEVELOPMENT OF LENTIVIRAL VECTORS FOR INHIBITION OF HEPATITIS B VIRUS VIA SMALL INTERFERING RNA	9
Incidence and Associated factors to development of hyponatremia in a cohort of ambulatory patients with compensated liver cirrhosis	9
Overlap syndrome: Report of a case and review of the literature.	9
Pirfenidone decreases insulin, glucagon, leptin, plasminogen activator inhibitor 1, preventing nonalcoholic steatohepatitis and myocarditis in an obesity moldel	9
P- 48 EFFECT OF THE COMBINATION OF ORLISTAT AND L-CARNITINE ON THE QUALITY OF LIFE (SF.36) IN 16 OVERWEIGTH PATIENTS	8
Clinical and epidemiological characterization of patients with hepatocarcinoma	8
P- 38 HEPATITIS E VIRUS IN PATIENTS WITH CHRONIC LIVER DISEASE IN COLOMBIA	8
P- 56 TUBERCULOSIS IN LIVER TRANSPLANT RECIPIENTS: EXPERIENCE OF A SINGLE CENTER	8
Lactate-albumin ratio as a predictor of mortality in patients with acute on chronic liver failure in a third-level care hospital in Mexico	8
P- 43 HCV TESTING AND TREATMENT IN FOUR BRAZILIANS’ CORRECTIONAL SETTINGS	8
P-57 CHARACTERIZATION OF HEPATOCELLULAR CARCINOMA AND ITS RELATIONSHIP WITH ALPHA-FETOPROTEIN LEVELS	8
O-1 SEROPREVALENCE AND MOTHER-TO-CHILD TRANSMISSION OF HEPATITIS B AND C VIRUSES AMONG PREGNANT WOMEN IN A MATERNAL AND CHILDREN HOSPITAL FROM THE PROVINCE OF BUENOS AIRES	8
O- 5 HCC RISK SCORE PRE AND POST SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS TREATED FOR CHRONIC HEPATITIS C	8
Secondary Attack Rate of Hepatitis C Virus (HCV)	7
Sclerosing cholangitis associated with IgG4 disease. Case Report	7
Serum determination of IL-1β and IL-1RA in patients with chronic liver diseases	7
P-40 IS THERE A DISTINCT PHENOTYPE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN LEAN AND OVERWEIGHT PATIENTS?	7
Giant simple hepatic cyst, when and how to treat it	7
Clinical characteristics, therapeutic approach, and outcomes in patients with hepatocellular carcinoma at a third-level hospital.	7
Pirfenidone ameliorates MAFLD by improving insulin sensitivity and reducing epididymal fat	7
P- 32 HEPATITIS A AND E VIRUSES IN CÓRDOBA, ARGENTINA: WASTEWATER-BASED EPIDEMIOLOGY AS A SILENT SENTINEL OF THE TREND OF VIRUS CIRCULATION IN THE COMMUNITY	7
P-52 MALNUTRITION IN COMPENSATED AND DECOMPENSATED LIVER CIRRHOSIS	7
Symptomatic giant cavernous hemangioma as an indication for liver transplantation	7
Observational Study of Biliary Duct stenosis in patients with Post-Liver Transplant	7
OP-2 ANALYSIS OF THE GENETIC DIVERSITY OF HEPATITIS DELTA VIRUS CIRCULATING IN BRAZIL BETWEEN 2013 AND 2021 AND ITS RELATIONSHIP WITH HEPATITIS B VIRUS	7
P-49 CONCENTRATION OF IL-12 AND CXCL-10 IN CHRONIC LIVER DISEASES	7
Evaluation of IL-12 and CXCL-10 in patients with hepatitis C, non-alcoholic fatty liver disease and liver damage for alcohol consumption	7
P-124 TITLE: CLINICAL CHARACTERISTICS OF CIRRHOTIC PATIENTS WITH VARICEAL BLEEDING IN A SINGLE CENTER EXPERIENCE. DESCRIPTIVE STUDY	6
P-29 INCIDENCE AND ASSOCIATED FACTORS OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION IN A SINGLE CENTER IN PERU: A RETROSPECTIVE STUDY.	6
P-21 FIBROSIS DEVELOPMENT AND MALIGNANCIES ARE DELAYED BY PIRFENIDONE WHILE INCREASING SIRT1 NUCLEAR TRANSLOCATION AND HISTONE 3 DEACETYLATIONS IN A HEPATOCARCINOMA MODEL	6
P- 44 HEPATOCELLULAR CARCINOMA IN CIRRHOTIC PATIENTS IN A PARAGUAYAN LIVER REFERENCE CENTER: CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS	6
P-5 THREE-DIMENSIONAL SINGLE-CELL ATLAS OF LIVER TISSUE ARCHITECTURE	6
P- 39 CLINICAL SIGNIFICANCE OF GRADE 1 HEPATIC ENCEPHALOPATHY IN PATIENTS HOSPITALIZED FOR COMPLICATIONS OF CIRRHOSIS	6
P1- HIGH VIRAL SUPPRESSION AND IMPROVED SAFETY PROFILE OF TENOFOVIR ALAFENAMIDE RELATIVE TO TENOFOVIR DISOPROXIL FUMARATE IN CHRONIC HEPATITIS B PATIENTS TREATED FOR 5 YEARS	6
O-33 PREVALENCE OF HIGH-RISK NON-ALCOHOLIC STEATOHEPATITIS ACCORDING TO THE FAST® INDEX IN A GROUP OF DIABETIC PATIENTS	6
P- 16 HEPATOCELLULAR CARCINOMA IN CENTRAL AMERICA: A MULTIDISCIPLINARY APPROACH IN A COSTA RICAN COHORT	6
P- 91 CHANGES IN EARLY VISUAL PERCEPTION IN PATIENTS WITH MINIMAL HEPATIC ENCEPHALOPATHY	6
P- 109 NON-INVASIVE ASSESSMENT OF FIBROSIS REGRESSION IN VIROLOGICAL RESPONDERS SUSTAINED BY HEPATITIS C VIRUS	6
P- 25 ANTIOXIDANT EFFECT OF MORINGA OLEIFERA IN A MURINE MODEL OF NONALCOHOLIC STEATOHEPATITIS	6
EDITORIAL BOARD	6
P-27 DESCRIPTIVE STUDY ON PATIENTS WITH HEPATOCARCINOMA IN A PUBLIC HOSPITAL 2018-2023	6
P- 81 PREVALENCE OF HEV INFECTION IN HIV CARRIERS, PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOTIC PATIENTS	6
Societal costs and survival of patients with biopsy-verified non-alcoholic steatohepatitis: Danish nationwide register-based study	5
Shutting those revolving doors	5
P- 9 BIOMARKERS OF THE BACTERIAL, VIRAL AND HUMAN GUT TRANSCRIPTOME IN METABOLIC ASSOCIATED FATTY LIVER DISEASE (MAFLD) IN ARGENTINA	5
An Acknowledgement	5
P-8 TRENDS IN ALCOHOL-ASSOCIATED CIRRHOSIS IN CHILE: A POPULATION STUDY BETWEEN 2001 TO 2020.	5
P- 45 ENDOSCOPIC ULTRASOUND SHEAR-WAVE ELASTOGRAPHY OF THE RIGHT AND LEFT HEPATIC LOBE PREDICTS LIVER CIRRHOSIS: A DIAGNOSTIC TRIAL	5
Characteristics and in-hospital outcomes of COVID-19 patients with abnormal liver biochemical tests	5
Development and validation of a noninvasive prediction model for significant hepatic liver fibrosis in Chinese patients with autoimmune hepatitis	5
Intravenous albumin in cirrhosis: Updated clinical uses and novel perspectives	5
Evaluation of drug-induced liver injury as etiology for acute liver failure in Brazil	5
Causality imputation between herbal products and HILI: An algorithm evaluation in a systematic review	5
Visualising and quantifying intestinal permeability -where do we stand	5
Occult liver disease: A multinational perspective	5
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later?	5
Neurofilament light chain but not glial fibrillary acidic protein is a potential biomarker of overt hepatic encephalopathy in patients with cirrhosis	5
Outcomes of hepatitis C virus seropositive donors to hepatitis C virus seronegative liver recipients: A large single center analysis	5
Ubiquitin-specific protease 1 acts as an oncogene and promotes lenvatinib efficacy in hepatocellular carcinoma by stabilizing c-kit	5
EIF3B affects the invasion and metastasis of hepatocellular carcinoma cells via the TGFBI/MAPK/ERK pathway	5
NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: A multi-center, retrospective study	5
Lactate-dehydrogenase associated with mortality in hospitalized patients with COVID-19 in Mexico: a multi-centre retrospective cohort study	5
Pregnancy in Chronic Liver Disease: Before and After Transplantation	5
Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists	5
P-118 METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: INDICATION FOR LIVER TRANSPLANTATION AND OCCURRENCE IN THE POSTOPERATIVE PERIOD	4

P-110 CHANGES IN THE CLINICAL PRESENTATION OF PRIMARY BILIARY CHOLANGITIS (PBC) OVER THE YEARS IN A UNIVERSITY CENTER IN ARGENTINA	4
P-91 NORMALIZATION OF ALKALINE PHOSPHATASE COMPARED TO CONVENTIONAL RESPONSE CRITERIA LEADS TO LOWER LIVER RELATED EVENTS AND MORTALITY IN PATIENTS LIVING WITH PRIMARY BILIARY CHOLANGITIS, TREATED WIT	4
P-85 IMPACT OF TECHNICAL NOTE No 32/2021 ON THE RATE OF LIVER TRANSPLANTS FOR REFRACTORY ASCITIS IN A TERTIARY HOSPITAL	4
O2- CHARACTERIZATION OF STEATOTIC LIVER DISEASE AND THE ROLE OF GENETIC BACKGROUND IN LATIN AMERICA	4
P-12 METHYL GROUP DONOR SUPPLEMENTATION IN A MetALD MODEL: REGULATION OF GUT MICROBIOTA AND METABOLIC PARAMETERS	4
P-32 ACCESSIBILITY TO SEQUENTIAL SYSTEMIC TREATMENT AFTER TACE: IMPACT ON SURVIVAL IN A LATIN AMERICAN PROSPECTIVE COHORT	4
P-42 ASSESSING THE TRAINING NEEDS OF PERUVIAN HEALTHCARE PROFESSIONALS	4
Nationwide marketing as a tool to increase literacy and awareness for living liver donation	4
P-22 URINARY BIOMARKER NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) FOR IDENTIFYING ACUTE KIDNEY INJURY IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS AND CIRRHOSIS	4
The changing impact of pre-liver transplant renal dysfunction on post-transplant survival: results of 2 decades from a single center	4
P-4 HYPOTHERMIC OXYGENATED PERFUSION USING AN ECMO DEVICE IN LIVER TRANSPLANTATION: AN ANALYSIS OF THE FIRST 100 CASES AT A CHILEAN PUBLIC HOSPITAL	4
P-113 EVALUATION OF THE MELNA AGIB SCALE TO PREDICT MORTALITY IN PATIENTS WITH CIRRHOSIS AND VARICEAL HEMORRHAGE	4
The epidemiology of non-alcoholic steatohepatitis (NASH) in the United States between 2010-2020: a population-based study	4
P-28 CHARACTERIZATION OF CHRONIC LIVER DISEASE, CIRRHOSIS, AND HEPATOCELLULAR CARCINOMA PROGRESSION IN A COLOMBIAN HEALTH MAINTENANCE ORGANIZATION: A TEN-YEAR RETROSPECTIVE STUDY	4
P-50 CLINICAL AND DEMOGRAPHIC CHARACTERISTICS OF PATIENTS WITH ACUTE HEPATITIS B VIRUS IN A PUBLICAL HOSPITAL IN CHILE FROM 2015 TO 2022.	4
P-11 REAL-WORLD DATA WITH PANGENOTYPIC DIRECT-ACTING ANTIVIRALS IN LATINAMERICA: PRELIMINARY RESULTS OF THE SVR10K STUDY	4
Develop and validate a novel online AIHI-nomogram to predict severe liver inflammation in patients with autoimmune hepatitis	4
P-92 CAN HONEY AND APICULTURAL DERIVATIVES HELP IN FATTY LIVER DISEASE?	4
Circ_0008285 knockdown represses tumor development by miR-384/RRM2 axis in hepatocellular carcinoma	4
P-69 EFFECTS OF POPULATIONAL-RELEVANT DOSES OF CARBOXYMETHYLCELLULOSE AND POLYSORBATE 80 EMULSIFIERS ON MASLD-ASSOCIATED HEPATOCARCINOGENESIS	4
P-109 ALKALINE PHOSPHATASE AND CIRRHOSIS AT DIAGNOSIS ARE ASSOCIATED WITH DEEP RESPONSE TO URSODEOXYCHOLIC ACID IN PRIMARY BILIARY CHOLANGITIS	4
P-119 POST-TRANSPLANT OVERALL AND GRAFT SURVIVAL AFTER LIVER TRANSPLANTATION FOR AUTOIMMUNE HEPATITIS	4
P-26 EPIGENETIC MARKS IN PATIENTS WITH SUSTAINED VIRAL RESPONSE TO HCV AND RESIDUAL LIVER FIBROSIS ARE RESTORED BY PROLONGED-RELEASE PIRFENIDONE	4
P-3 FACTORS ASSOCIATED WITH AN IMPROVEMENT IN SEQUENTIAL LIVER STIFFNESS MEASURES BY TRANSIENT ELASTOGRAPHY IN MASLD PATIENTS WITH PREDIABETES AND TYPE 2 DIABETES.	4
OP- 11 Detection Strategy for Patients with Viral Hepatitis Using Laboratory Records of Blood Samples for HBsAg and HCV Antibodies: PANRELINK	4
P-25 IMPEDANCE CARDIOGRAPHY AND SPLEEN STIFFNESS MEASUREMENT TO ASSESS THERAPEUTIC RESPONSE IN CIRRHOTIC PATIENTS TREATED WITH NON-CARDIOSELECTIVE BETA-BLOCKERS	4
Examining genetic associations with hepatic steatosis in Mexican-origin adults	4
P-46 IMMUNOSUPPRESSION IN POST LIVER TRANSPLANTATION: REVIEW OF THE EXPERIENCE IN A CHILEAN UNIVERSITY HOSPITAL	4
Lipocalin-2 silencing alleviates sepsis-induced liver injury through inhibition of ferroptosis	4
Development of a biodegradable prosthesis through tissue engineering, for the organ-replacement or substitution of the extrahepatic bile duct	3
Genomic instabilities in hepatocellular carcinoma: biomarkers and application in immunotherapies	3
From Child-Pugh to MELD score and beyond: Taking a walk down memory lane	3
IL-6/STAT3 signaling pathway induces prostate apoptosis response protein-4(PAR-4) to stimulate malignant behaviors of hepatocellular carcinoma cells	3
Elevated lactate/albumin ratio as a novel predictor of in-hospital mortality in hospitalized cirrhotics	3
The steatosis-associated fibrosis estimator (SAFE) outperformed the FIB-4 score in screening the population for liver disease	3
The impact of electronic medical record system implementation on HCV screening and continuum of care: a systematic review	3
Clinical and microbiological characteristics of bacterial infections in patients with cirrhosis. A prospective cohort study from Argentina and Uruguay	3
Acid-base abnormalities and liver dysfunction	3
Circ-LARP1B knockdown restrains the tumorigenicity and enhances radiosensitivity by regulating miR-578/IGF1R axis in hepatocellular carcinoma	3
Magnitude and genotype of hepatitis delta virus among chronic hepatitis B carriers with a spectrum of liver diseases in Ethiopia	3
The myth of the stigma of fatty liver: What does the evidence show?	3
Study on the prediction model of liver cancer based on chronic liver disease and the related molecular mechanism	3
Correspondence: “A multisociety Delphi consensus statement on new fatty liver disease nomenclature”	3
Prevalence of fatty liver disease after liver transplantation and risk factors for recipients and donors	3
Tumor-associated macrophages contribute to cholangiocarcinoma progression and chemoresistance through activation of ID1	3
Prevalence and impact of Sjögren's syndrome in primary biliary cholangitis: a systematic review and meta-analysis	3
Anti-gp210-positive primary biliary cholangitis: The dilemma of clinical treatment and emerging mechanisms	3
Comparison of diagnostic performance of AFP, DCP and two diagnostic models in hepatocellular carcinoma: a retrospective study	3
A practical approach to the endoscopic management of biliary strictures after liver transplantation	3
“THE EFFECT OF GROWTH DIFFERENTIATION FACTOR 11 (GDF11) ON THE RESPONSE OF TUMOR-ASSOCIATED MACROPHAGES IN HEPATOCELLULAR CARCINOMA DERIVED CELLS”	3
Gut-related molecules as potential biomarkers in patients with decompensated cirrhosis	3
Predictors of poor postoperative outcomes in liver transplant patients	3
Immune checkpoint and angiogenic inhibitors for the treatment of hepatocellular carcinoma: It takes two to tangle	3
The impact of COVID-19 on the cascade of care of HCV in the US and China	3
Role of waist circumference, body mass index and high-sensitivity C-reactive protein in pediatric steatotic liver disease: A cross-sectional study	3
Integrated analyses and a novel nomogram for the prediction of significant fibrosis in patients	3
Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma." Review article	3
Dietary macro and micronutrients associated with MASLD: Analysis of a national US cohort database	3
Liver decompensation is a frequent cause of treatment discontinuation and prognostic factor in intermediate-advanced HCC	3
MiR-20b-5p promotes hepatocellular carcinoma cell proliferation, migration and invasion by down-regulating CPEB3	3
Non-invasive diagnosis of non-alcoholic fatty liver disease using an algorithm combining clinical indexes and ultrasonographic measures	3
Racial, ethnic, and socioeconomic disparities impact post-liver transplant survival in patients with hepatocellular carcinoma	3
Trajectories of patients relisted for liver transplantation	2
Outcomes and factors associated with relapse of vaccine-induced liver injury after SARS CoV-2 immunization: A nationwide study	2
The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease	2
miRNA-338-3p/CAMK IIα signaling pathway prevents acetaminophen-induced acute liver inflammation in vivo	2
Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents	2
Identification of key genes associated with the progression of liver fibrosis to hepatocellular carcinoma based on iTRAQ proteomics and GEO database	2
MiR-326 sponges TET2 triggering imbalance of Th17/Treg differentiation to exacerbate pyroptosis of hepatocytes in concanavalin A-induced autoimmune hepatitis	2
P-10 LATIN AMERICAN REGISTRY OF CHOLANGIOCARCINOMA: CLINICAL FEATURES, MANAGEMENT AND OUTCOMES	2
Reply to: “From NAFLD to MASLD: Promise and pitfalls of a new definition’	2
Patients with alcohol-related liver disease hospitalized during the COVID-19 pandemic experienced worse outcomes	2
NAFLD-MASLD-MAFLD continuum: A swinging pendulum?	2
From evidence to clinical practice: Bridging the gap of new liver cancer therapies in Latin America.	2
Association between klotho and non-alcoholic fatty liver disease and liver fibrosis based on the NHANES 2007–2016	2
A call for unity: The path towards a more precise and patient-centric nomenclature for NAFLD	2
Clinical features and treatment outcomes of primary biliary cholangitis in a highly admixed population	2
Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFT	2
HBX suppresses PTEN to promote the malignant progression of hepatocellular carcinoma through mi-R155 activation	2
Performance of eight predictive models for hepatocellular carcinoma recurrence after liver transplantation: A comparative study	2
Drug-induced liver injury: A management position paper from the Latin American Association for Study of the liver	2
Non-linear associations of circulating total bilirubin concentration with the risk of nonalcoholic fatty liver disease and all-cause mortality	2
Weekend catch-up sleep is associated with the alleviation of non-alcoholic fatty liver disease	2
Liver transplant outcomes during the COVID-19 pandemic	2
An exploratory analysis of patient factors influencing acceptance of extended criteria liver grafts	2
The role of inflammasomes in hepatocellular carcinoma: Mechanisms and therapeutic insights	2
Gradual dosing of ursodeoxycholic acid in mothers with intrahepatic cholestasis of pregnancy may improve composite neonatal outcome	2
Prevalence and mortality prognosis of steatotic liver disease phenotypes	2
Silencing lncRNA NEAT1 reduces nonalcoholic fatty liver fat deposition by regulating the miR-139-5p/c-Jun/SREBP-1c pathway	2
Deep stool microbiome analysis in cirrhosis reveals an association between short-chain fatty acids and hepatic encephalopathy	2
Alcohol-associated liver disease: Epidemiology and management	2
Editorial board	2
Introduction of a standardized protocol for cardiac risk assessment in candidates for liver transplant – A retrospective cohort analysis	2
Emerging biomolecules for practical theranostics of liver hepatocellular carcinoma	2
Building a culture of scientific integrity among the academic and research communities of Latin America	2